Francesca Bergamo retweetledi
Tremelimumab & durvalumab as neoadjuvant or definitive management of dMMR/MSI GC or GEJ adenocarcinoma
@Annals_Oncology
doi.org/10.1016/j.anno…
🔎 INFINITY by GONO
👉pCR: 60%; MPR 80%; 24-mo PFS 85% & OS 92%
👉76% cCR > NOM
🧐excellent efficacy for chemo-free T300/D
@myESMO
English